Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study)

• References

• 1 Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257 (14) 7944-7.
• 2 Esmon NL, Carroll RC, Esmon CT. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983; 258 (20) 12238-42.
• 3 Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477 1-2 349-60.
• 4 Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29 (Suppl. 07) S48-S51.
• 5 Ireland H, Kyriakoulis K, Kunz G. et al. Directed search for thrombomodulin gene mutations. Haemostasis 1996; 26 (Suppl. 04) 227-32.
• 6 Ohlin AK, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997; 78 (01) 396-400.
• 7 Norlund L, Zoller B, Ohlin AK. A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis. Thromb Haemost 1997; 78 (04) 1164-6.
• 8 van der Velden PA, Krommenhoek-Van EsT, Al-laart CF. et al. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia. Thromb Haemost 1991; 65 (05) 511-3.
• 9 Hayashi T, Zushi M, Yamamoto S. et al. Further localization of binding sites for thrombin and protein C in human thrombomodulin. J Biol Chem 1990; 265 (33) 20156-9.
• 10 Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cefaclor activity. J Biol Chem 1992; 267 (09) 6164-70.
• 11 Wu KK, Aleksic N, Ahn C. et al. Thrombomodulin Ala455 Val polymorphism and risk of coronary heart disease. Circulation 2001; 103 (10) 1386-9.
• 12 Norlund L, Holm J, Zoller B. et al. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost 1997; 77 (02) 248-51.
• 13 Le Flem L, Mennen L, Aubry ML. et al. Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. Arterioscler Thromb Vase Biol 2001; 21 (03) 445-51.
• 14 Dittman WA, Nelson SC, Greer PK. et al. Characterization of thrombomodulin expression in response to retinoic acid and identification of a retinoic acid response element in the human thrombomodulin gene. J Biol Chem 1994; 269 (24) 16925-32.
• 15 Yu K, Morioka H, Fritze LM. et al. Transcriptional regulation of the thrombomodulin gene. J Biol Chem 1992; 267 (32) 23237-47.
• 16 Kwok S, Kellogg DE, McKinney N. et al. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 1990; 18 (04) 999-1005.
• 17 O’Dell SD, Gaunt TR, Day IN. SNPgenotyp-ing by combination of 192-well MADGE, ARMS and computerized gel image analysis. Biotechniques 2000; 29 (03) 500-6.
• 18 Day IN, Humphries SE. Electrophoresis for genotyping: microliter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 1994; 222 (02) 389-95.
• 19 Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility. Atheroscler Thromb Vase Biol. 2004 (hi press).
• 20 Man-Vague I, Morange PE, Aubert H. et al. On behalf of the HIFMECH Study group. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen concentration and TAFI genotype in relation to myocardial infarction in the North and South of Europe. Atheroscler Throm Vase Biol 2002; 22: 867-73.
• 21 Chakravarti A, Buetow KH, Antonarakis SE. et al. Nonuniform recombination within the human beta-globin gene cluster. Am J Hum Genet 1984; 36 (06) 1239-58.
• 22 Kern PA, Saghizadeh M, Ong JM. et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95 (05) 2111-9.
• 23 Yudkin JS, Stehouwer CD, Emeis JJ. et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vase Biol 1999; 19 (04) 972-8.
• 24 Yudkin JS. Relationship of serum C3 complement with insulin resistance and coronary heart disease-cause, consequence or common antecedent?. Eur Heart J 2000; 21 (13) 1036-9.
• 25 Ziccardi P, Nappo F, Giugliano G. et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105 (07) 804-9.
• 26 Mendall MA, Patel P, Asante M. et al. Relation ofserumcytokineconcentrationstocardiovas-cular risk factors and coronary heart disease. Heart 1997; 78 (03) 273-7.
• 27 Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73 (01) 159-65.
• 28 Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and post-transcriptional mechanisms. Blood 1991; 77 (03) 542-50.
• 29 Speiser W, Kapiotis S, Kopp CW. et al. Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost 2001; 85 (02) 362-7.